Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17443117 | 1.00 | CTSL (0.43) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL2647154 | 1.00 | CTSL (0.43) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL21570696 | 0.94 | CTSL (0.41) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL4136007 | 0.91 | OPRM1 (0.43) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL25525463 | 0.91 | OPRM1 (0.43) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL717952 | 0.87 | OPRM1 (0.49) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL4442781 | 0.86 | CTSL (0.42) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL445076 | 0.84 | CTSL (0.43) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL9895268 | 0.84 | CTSL (0.38) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL9895267 | 0.84 | CTSL (0.38) | CTSLCTSBCTSKOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103475-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| EP-4584266-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250170112-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4536224-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025038783-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS OR CHRONIC HEART FAILURE | LUCY THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| CN-119421709-A | Indazole-containing macrocyclic compounds and uses thereof | 荣山医药股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2155716-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | Pfizer Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008139288-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-6828322-B2 | Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine | MERCK SHARP & DOHME LTD. | 2004-12-07 | — | — | US | disclosed |
| US-20040063714-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | CARLING WILLIAM ROBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| US-6579875-B1 | Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine | MERCK SHARP & DOHME LIMITED | 2003-06-17 | — | — | US | disclosed |
| EP-1049696-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037644-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063714-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | GABRA3, GABBR1, GABRA2 | CTSL 4658/4885CTSB 4384/4885CTSK 4387/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CTSL 50/4885CTSB 1141/4885CTSK 1705/4885 |
| US-20250170112-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ADORA2A, ADORA1, PDE7A | CTSL 3927/4885CTSB 3067/4885CTSK 2981/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | CTSL 2428/4885CTSB 2765/4885CTSK 1290/4885 |
| US-20260103475-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K4 | CTSL 2930/4885CTSB 3803/4885CTSK 1161/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | CTSL 3077/4885CTSB 2931/4885CTSK 4250/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | CTSL 1996/4885CTSB 2780/4885CTSK 1897/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | CTSL 1996/4885CTSB 2780/4885CTSK 1897/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CTSL 50/4885CTSB 1141/4885CTSK 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.